In light of recent efforts to boost capital markets activity and attract high-growth companies to list locally, significant IPO reforms have been introduced in 2025. Gain insights into ASIC’s new fast-track IPO regime and recent amendments to ASX Guidance Note 1, with a focus on how these changes impact the listing process. Understand the practical implications for early-stage technology, including timing, disclosure, and regulatory engagement. Explore the broader context of these reforms and assess their potential to reshape the IPO landscape.
Friday, 10 October 2025
Description
Attend and earn 1 CPD unit in Substantive Law
This program is applicable to practitioners from all States & Territories
1.00pm to 2.00pm ASX IPO Reforms 2025: ASIC’s Fast-Track Regime and Updates to ASX Guidance Note 1 – Applying for Admission
- Understand ASIC’s new fast-track IPO regime
- Explore recent amendments to ASX Guidance Note 1, particularly in respect of the implications for early-stage technology and biotechnology sectors
- Provide an overview of the listing process and the potential for broader reforms to attract new listings
Presented by Kate Naude, Partner and Clare Brown, Partner, Johnson Winter Slattery
Presenters
Kate Naude, Partner, Johnson Winter Slattery
Kate is an experienced corporate lawyer with deep expertise in M&A (public and private) and equity capital markets, acting for corporates and private capital clients across the technology, healthcare and energy sectors. She has extensive experience in ECM transactions including IPOs, rights issues, placements and share purchase plans. She also specialises in public and private M&A transactions including takeover bids, schemes of arrangement and private treaty transactions. Kate acts for ASX-listed companies in relation to their corporate transactions and also acts for private equity and venture capital firms in relation to their Australian investments. She has previously worked for major Australian banks in their in-house M&A legal teams.
Clare Brown, Partner, Johnson Winter Slattery
Clare specialises in corporate and securities law, with a particular focus on equity capital markets, venture capital and M&A. She has experience in cross-border and domestic corporate transactions including advising on equity fundraisings, private financing and investment transactions, regulated and private M&A, joint ventures, and securities regulatory and ASX compliance issues. Clare also advises on corporate governance matters and employee equity schemes. She regularly acts for companies and investors in the healthcare, medical device and biotechnology sector, as well as the technology industry more broadly. Clare also regularly represents early and growth stage companies and the venture capital firms that invest in them. Clare has significant experience advising US clients doing business in Australia and Australian clients doing business in the US, including having acted for a number of US companies listed on ASX.
